India Drug Delivery Devices Market Size, Share Outlook, Growth Analysis Report and Forecast Trends 2026-2030

The India Drug Delivery Devices Market forms a significant portion of the Asia-Pacific pharmaceutical delivery sector, with the market estimated at USD 12.70 billion in 2024 and forecast to reach USD 18.05 billion by 2030. The market covers a wide range of delivery technologies including prefilled syringes, autoinjectors, pen injectors, inhalers, transdermal patches, and implantable devices, serving therapeutic areas such as diabetes, oncology, respiratory diseases, and infectious diseases.

• •India's domestic pharmaceutical industry ranks among the largest globally, providing a strong manufacturing base for drug delivery devices
• •Rising domestic demand for biologic drugs and biosimilars is driving adoption of advanced delivery devices
• •Government schemes like the PLI for pharmaceutical production are encouraging local device manufacturing and reducing import dependence

The market is propelled primarily by India's status as the world's diabetes capital, with over 77 million diagnosed diabetics driving demand for pen injectors and insulin delivery systems. Additionally, growing awareness of self-administration and home healthcare is increasing adoption of user-friendly devices, while the expanding biologics pipeline requires sophisticated delivery mechanisms. Improvements in healthcare infrastructure and rising per capita healthcare spending further underpin market expansion.

• •India's large and growing diabetic population is a primary catalyst for demand in insulin pens, autoinjectors, and needle-free delivery technologies
• •Rising prevalence of chronic conditions such as cardiovascular disease and respiratory disorders is broadening the application base for drug delivery devices
• •Government programs like Ayushman Bharat and increased healthcare budget allocations are expanding access to advanced therapeutics and their delivery systems

The market is segmented by product type, including injection devices (prefilled syringes, autoinjectors, pen injectors), inhalers, transdermal patches, and implantable devices. By application, diabetes care dominates, followed by oncology, respiratory diseases, and infectious disease treatments. Regionally, major demand originates from metropolitan areas and tier-1 cities, though tier-2 and tier-3 cities are increasingly contributing as healthcare access improves.

• •Injection and infusion devices represent the largest product segment, fueled by biologics and biosimilar adoption across therapeutic areas
• •Diabetes treatment accounts for the leading application segment, supported by India's high disease burden and insulin market growth
• •West and South India currently lead in market adoption, with North and East regions showing accelerating growth trajectories

What are the recent trends and outlook?

The market is moving toward connected and smart drug delivery devices integrated with digital health platforms, enabling adherence monitoring and remote patient management. Sustainability considerations are influencing device design, with manufacturers exploring eco-friendly materials and recyclable components. The long-term outlook remains positive as India's pharmaceutical ecosystem matures, domestic R&D capabilities strengthen, and the country solidifies its position as a global hub for both drug development and advanced delivery solutions.

• •Digital health integration is gaining momentum, with connected injectors and smart inhalers enabling real-time patient monitoring and data-driven adherence management
• •The biosimilars and follow-on biologics wave in India is expected to create sustained demand for interchangeable and high-precision delivery devices through 2030 and beyond
• •Investment in local R&D and manufacturing of drug-device combinations is accelerating, positioning India as a competitive export destination for affordable delivery technologies